



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

[Handwritten mark]

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/828,143	03/24/97	HSIA	H 24400-101

HM22/0629

LYON & LYON
ATTN: KURT T. MULVILLE
633 WEST FIFTH STREET, SUITE 4700
LOS ANGELES, CA 90071-2066

EXAMINER

MARX, I

ART UNIT	PAPER NUMBER
----------	--------------

1651

19

DATE MAILED: 06/29/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

08/828,143

Applicant(s)

Hsia

Examiner

Irene Marx

Group Art Unit

1651



☒ Responsive to communication(s) filed on Jun 5, 2000

☒ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

☒ Claim(s) 9-11, 16-20, and 24-32 is/are pending in the application.

Of the above, claim(s) 9-11 is/are withdrawn from consideration.

☐ Claim(s) _____ is/are allowed.

☒ Claim(s) 16-20 and 24-32 is/are rejected.

☐ Claim(s) _____ is/are objected to.

☐ Claims _____ are subject to restriction or election requirement.

Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
☐ received.

☐ received in Application No. (Series Code/Serial Number) _____.

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

☐ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

The amendment filed 6/5/00 is acknowledged. Claims 16-20 and 24-32 are being considered on the merits. Claims 9-11 are withdrawn from consideration.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 16-20 and 24-32 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

No basis or support is found in the present specification for the recitation in claim 16 "wherein the viability of the bacteria in the composition does not decrease for a period of at least ten months when the composition is stored in an airtight container", in claim 20 for "wherein the viability of the bacteria in the composition does not decrease for a period of at least twelve months when the composition is stored in an airtight container", in claim 26 for "wherein the viability of the bacteria in the composition does not decrease for a period of at least eighteen months when the composition is stored in an airtight container"

No basis or support is found in the present specification for the recitation of "dry" weight in the claims.. In the specification at page 9, lines 19-25 the percentage is based on the total mass of the mixture composition. No indication of dry or wet weight is found.

Therefore, this material raises the issue of new matter and should be deleted.

Applicants' arguments have been fully considered but they are not deemed to be persuasive.

Applicants argue that there is support for the lack of decrease in viability at the table in Example 2, and page 10, lines 16-20. However, Example 2 pertains exclusively to the viability of the bacterial composition of Example 1 and not to unidentified bacteria, yeast or protein as

claimed for an unlimited period of time, that includes decades and centuries. Moreover, the disclosure at page 10, lines 16-20 pertains to the protein source and is not informative regarding the issue at hand..

The basis of applicant's assertions that one having ordinary skill in the art of food preparation would at the time the claimed invention was made have understood that "% of total mass" used in the application and claims to mean the "% dry weight of the dry compositions" is not set forth (Response, page 5, paragraph 2). That the composition of example 1 is comprised of specific ingredients provided by one or more commercial sources is not dispositive of whether one of ordinary skill in the food art would or would not mix bacteria, yeast and protein prior to freeze drying, for example. Similarly, providing ingredients that are "dried" in a composition comprising a mixture of ingredients cannot be construed as meaning that all of the components are necessarily weighed after drying.

It is also of interest to note that the original claims 3 and 7 are directed to certain percentages of the "total mass" of the composition. There is nothing on the record to fairly suggest to one of ordinary skill in the art that the correct interpretation of this recitation is "percent dry weight".

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 16, 17, 19 and 21 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Levy (EP 430736) in light of Prescott *et al.* for the reasons as stated in the last Office action and the further reasons below.

Applicant's contentions regarding the amounts used by Levy are noted. However, the invention as claimed fails to identify the type of bacteria, yeast or protein to be used for the methods. Therefore, there is no reason to conclude, for example, that the "protein" component necessarily must be non-yeast or non-bacterial, and the amounts may be calculated accordingly.

Applicant's arguments regarding lack of disclosure in Prescott of yeast as being particularly "concentrated source of protein" is puzzling. It is unclear what applicant considers to be a particularly concentrated source of protein. In the present written disclosure applicant fails to define with any specificity what is intended by a "protein concentrate". Therefore, the standard to be applied to ascertain whether a given protein does or does not constitute a "protein concentrate" is uncertain in the present disclosure. The degree of concentration is not defined with any particularity. In addition there is no indication in the present specification as-filed that applicant intended to exclude yeast protein as a concentrated form of protein, whether or not this is so disclosed by Prescott.

Applicant's emphasis on what is shown in the examples of Levy appears misplaced, considering that the invention as claimed is not based with any specificity on the example herein.

Regarding "viability", there is nothing on the record to suggest that the tablets of Levy are subject to a decrease in viability that is greater than that of applicant's composition. Inasmuch as the nature of the bacteria, yeast and protein are substantially the same, viability can be presumed to be substantially the same, whether or not this property is or is not explicitly disclosed.

Applicant's attention is also directed to the new matter rejection *supra* regarding the touted viability properties of the as claimed composition.

Therefore the rejection is deemed proper and it is adhered to.

Claims 16-20 and 24-32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Levy taken with Prescott *et al.*, Jolly, Friend and El-Megeed *et al.*.

Applicants' arguments as they pertain to the above rejection have been fully considered but they are not deemed to be persuasive.

Applicants argue the viability of the bacteria in the composition does not decrease for a period of at least ten months when the composition is stored in an airtight container. Yet there is nothing on the record to provide basis or support for this claim, as noted in the rejection under 35 U.S.C § 112, regarding new matter. Applicants have demonstrated stability up to 18 months with a specific composition containing commercial grade components in specific amounts, wherein the viable bacteria are *Lactobacillus acidophilus*, the yeast is debittered brewer's yeast and the protein is soy protein isolate (Example 1, page 12). There is nothing on the record to demonstrate or fairly suggest that the tablets of Levy are subject to a decrease in viability that is greater than that of applicant's composition. Inasmuch as the nature of the bacteria, yeast and protein that constitute the composition of the invention are not claim designated, they do not appear to be critical elements of the invention.

As to the arguments that the yeast material is intended to provide nutrients for the *Lactobacillus*, applicants have not indicated when the nutrients are to intended be used by the solid, dried, viable *Lactobacillus*. Applicant argues the merits of prolonging viability of *Lactobacillus* (Response, page 18, paragraph 2). Yet the claims are directed to "bacteria", except for claims 18, which recites a variety of bacteria that actually include *Lactobacillus* in the grouping. Therefore, these arguments are not persuasive of error in the rejection.

The stable preparation shown in the specification at page 12, Example 1, contains a large amount of soy protein, and the amount of yeast is greater than the amount of *L. acidophilus*. There is no clear correlation between this example and the invention as claimed.

The scope of the showing must be commensurate with the scope of claims to consider evidence probative of unexpected results, for example. In re Dill, 202 USPQ 805 (CCPA, 1979), In re Lindner 173 USPQ 356 (CCPA 1972), In re Hyson, 172 USPQ 399 (CCPA 1972), In re Boesch, 205 USPQ 215, (CCPA 1980), In re Grasselli, 218 USPQ 769 (Fed. Cir. 1983), In re Clemens, 206 USPQ 289 (CCPA 1980). It should be clear that the probative value of the data is not commensurate in scope with the degree of protection sought by the claim.

Therefore the rejection is deemed proper and it is adhered to.

Applicants have not demonstrated any unexpected properties of the composition as claimed.

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Irene Marx whose telephone number is (703) 308-2922.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743. The appropriate fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196 .



Irene Marx
Primary Examiner
Art Unit 1651